Pro Mis Neurosciences Inc. PMN
We take great care to ensure that the data presented and summarized in this overview for ProMIS Neurosciences Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PMN
View all-
Great Point Partners LLC Greenwich, CT2.65MShares$1.56 Million1.62% of portfolio
-
Armistice Capital, LLC New York, NY2.51MShares$1.48 Million0.03% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.93MShares$1.14 Million0.37% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY1.59MShares$939,6361.68% of portfolio
-
Altium Capital Management LP New York, NY581KShares$343,0230.18% of portfolio
-
Allostery Investments LP Stamford, CT195KShares$115,1150.19% of portfolio
-
Heights Capital Management, Inc San Francisco, CA160KShares$94,5220.08% of portfolio
-
Bank Of Montreal Toronto, A630.4KShares$17,9150.0% of portfolio
-
Hara Capital LLC Bellevue, WA29.4KShares$17,3550.02% of portfolio
-
Ieq Capital, LLC26KShares$15,3640.0% of portfolio
Latest Institutional Activity in PMN
Top Purchases
Top Sells
About PMN
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Insider Transactions at PMN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Feb 10
2025
|
Neil Cashman Chief Scientific Officer |
BUY
Open market or private purchase
|
Indirect |
15,000
+47.44%
|
$0
$0.97 P/Share
|
|
Sep 24
2024
|
Madge K. Shafmaster Director |
BUY
Open market or private purchase
|
Direct |
70,000
+25.15%
|
$70,000
$1.3 P/Share
|
|
Sep 23
2024
|
Madge K. Shafmaster Director |
BUY
Open market or private purchase
|
Direct |
70,000
+33.6%
|
$70,000
$1.28 P/Share
|
|
Sep 20
2024
|
Madge K. Shafmaster Director |
BUY
Open market or private purchase
|
Direct |
60,000
+46.75%
|
$60,000
$1.25 P/Share
|
|
Sep 17
2024
|
Michael S Gordon > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
16,292
+14.88%
|
$16,292
$1.4 P/Share
|
|
Sep 16
2024
|
Michael S Gordon > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
76,931
+50.0%
|
$76,931
$1.22 P/Share
|
|
Aug 14
2024
|
Patrick D. Kirwin Director |
BUY
Open market or private purchase
|
Direct |
10,000
+13.7%
|
$10,000
$1.25 P/Share
|
|
Jul 31
2024
|
Jeremy M. Sclar > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
300,000
+9.99%
|
-
|
|
Jul 31
2024
|
Jeremy M. Sclar > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
697,674
+32.22%
|
-
|
|
Jul 31
2024
|
Michael S Gordon > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
500,000
+19.41%
|
-
|
|
Jul 31
2024
|
Michael S Gordon > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
465,116
+22.79%
|
-
|
|
Jul 31
2024
|
19 Promis Title > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
500,000
+19.41%
|
-
|
|
Jul 31
2024
|
19 Promis Title > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
465,116
+22.79%
|
-
|
|
Aug 23
2023
|
Max A. Milbury Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,297
+47.0%
|
-
|
|
Aug 23
2023
|
Neil Cashman Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,643
+8.59%
|
-
|
|
Aug 23
2023
|
Gavin T. Malenfant Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,660
+50.0%
|
-
|
|
Aug 23
2023
|
Patrick D. Kirwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+17.19%
|
-
|
|
Aug 23
2023
|
Gail M Farfel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,192
+49.08%
|
-
|
|
Dec 16
2022
|
Eugene Williams Director |
BUY
Open market or private purchase
|
Direct |
2,000
+0.62%
|
$8,000
$4.65 P/Share
|
|
Dec 15
2022
|
Patrick D. Kirwin Director |
BUY
Open market or private purchase
|
Indirect |
2,000
+6.67%
|
$8,000
$4.51 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.95M shares |
|---|---|
| Conversion of derivative security | 1.3M shares |